Lipella Pharmaceuticals Statistics
Total Valuation
LIPO has a market cap or net worth of 2.26 million. The enterprise value is -243,060.
| Market Cap | 2.26M |
| Enterprise Value | -243,060 |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
LIPO has 4.62 million shares outstanding. The number of shares has increased by 153.96% in one year.
| Current Share Class | 4.62M |
| Shares Outstanding | 4.62M |
| Shares Change (YoY) | +153.96% |
| Shares Change (QoQ) | +109.32% |
| Owned by Insiders (%) | 6.31% |
| Owned by Institutions (%) | 1.31% |
| Float | 4.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.82 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 0.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.04 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.60, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.60 |
| Quick Ratio | 3.78 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -248.36% and return on invested capital (ROIC) is -145.29%.
| Return on Equity (ROE) | -248.36% |
| Return on Assets (ROA) | -118.45% |
| Return on Invested Capital (ROIC) | -145.29% |
| Return on Capital Employed (ROCE) | -188.18% |
| Revenue Per Employee | 78,361 |
| Profits Per Employee | -920,053 |
| Employee Count | 7 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -0.05 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 9,971 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.39 |
Income Statement
In the last 12 months, LIPO had revenue of 470,163 and -5.52 million in losses. Loss per share was -2.54.
| Revenue | 470,163 |
| Gross Profit | -3.42M |
| Operating Income | -5.60M |
| Pretax Income | -5.52M |
| Net Income | -5.52M |
| EBITDA | -5.59M |
| EBIT | -5.60M |
| Loss Per Share | -2.54 |
Balance Sheet
The company has 2.78 million in cash and 274,539 in debt, giving a net cash position of 2.51 million or 0.54 per share.
| Cash & Cash Equivalents | 2.78M |
| Total Debt | 274,539 |
| Net Cash | 2.51M |
| Net Cash Per Share | 0.54 |
| Equity (Book Value) | 2.74M |
| Book Value Per Share | 0.61 |
| Working Capital | 2.69M |
Cash Flow
| Operating Cash Flow | -4.50M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,190.03% |
| Pretax Margin | -1,174.13% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LIPO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -153.96% |
| Shareholder Yield | -153.96% |
| Earnings Yield | -243.81% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 8, 2024. It was a reverse split with a ratio of 0.125.
| Last Split Date | Nov 8, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.125 |
Scores
LIPO has an Altman Z-Score of -7.68 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.68 |
| Piotroski F-Score | 2 |